Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

The use of amphotericin B is limited by numerous adverse effects. Infusion-related adverse events (IRAE) comprise chills, rigors, fever, hypotension or hypertension, hypoxia, nausea, vomiting, and hypokalaemia sometimes resulting ventricular fibrillation. About 50% of the patients on treatment with conventional amphotericin B deoxycholate are affected by IRAE. Probably, pro-inflammatory cytokines and immunostimulation via Toll-like receptors (TLRs) are involved in IRAE [15‐17].

Deterioration of renal function with an increase in serum creatinine is observed in as many as 80% of patients on treatment with amphotericin B deoxycholate. In about 40%, doubling of baseline creatinine is reported [16, 18‐26]. The renal toxicity is caused by vasoconstriction of the afferent arteriole resulting in a reduction of renal blood flow and glomerular filtration rate combined with tubular injury resulting in loss of potassium, magnesium, bicarbonate, and amino acids. A daily dose of >35 mg/d, a body weight >90 kg, male sex, simultaneous administration of nephrotoxic medications such as aminoglycosides or cyclosporine A are risk factors for renal adverse effects [15]. Rarely, anaemia and haemolysis have been observed during amphotericin B treatment. Whereas hypokalaemia is a common adverse effect of amphotericin B, excessive hyperkalaemia with cardiac arrest has also been observed [27].

All commercially available amphotericin B formulations have to be administered by intravenous infusion, because their enteral absorption is negligible. In plasma, 95–99% of amphotericin B is protein-bound, mainly to LDL, albumin and α-1-acid glycoprotein [28, 29]. Infusion of a 1-mg test dose prior to the therapeutic dose is recommended to identify patients who are intolerant. Subsequently, 0.25–0.3 mg/kg once daily should be applied and the daily dose should be increased by 5–10 mg per day until the maintenance dose of 0.6–1.0 mg/kg once daily is reached. For eradication of highly resistant fungi, a dose up to 1.5 mg/kg per day might be considered. Prolonged infusion over ≥6 h is particularly important in these cases. After administration of amphotericin B deoxycholate, amphotericin B is eliminated from plasma with a half-life (t _½ β) of ~24 h and a clearance of 10 to ~30 ml/kg/h. Its apparent volume of distribution (V _d) is 0.5–2.0 L/kg. The peak level (C _max) was ~2 µg/mL after standard doses of ~1 mg/kg body weight. An infusion time (T _inf) of ≥4 h is required to warrant tolerability [30‐34]. Twenty percent of labelled amphotericin B have been detected in the urine and ~40% in the faeces within a week after administration. This is probably unchanged amphotericin B because no amphotericin B metabolism has been detected so far (see Table 1) [28, 35‐37].

As high amphotericin B peak concentrations appear to correlate with its toxicity continuous infusion has been tried to enhance its tolerability. This approach was first reported by Chabot et al. [38]. Later on, 5-h infusion of amphotericin B deoxycholate was compared with continuous infusion in a randomized open-label trial. IRAE were significantly less frequent, and the increase in serum creatinine was lower in the continuous infusion group. The mortality was significantly lower in patients on continuous amphotericin B infusion (0 versus 18% at the end of treatment, 10 versus 30% after a 3-month follow up) [22]. In a retrospective study, renal deterioration as defined by a doubling of serum creatinine has been investigated. Treatment efficacy was a second endpoint. A median increase in serum creatinine by 50 and 85% was found in patients on continuous infusion and in patients on 4-h infusions, respectively. Renal impairment was significantly less frequent in patients who had received amphotericin B as a continuous infusion (P < 0.001). Fourteen-day survival was 95% in the continuous infusion cohort and only 79% in the group on 4-h infusion (P = 0.03) [39]. In addition, several observational studies on continuous amphotericin B infusion have been performed. In six patients who had undergone lung transplantation and obtained amphotericin B by continuous infusion (1 mg/kg/day, 40 days on average) and nephrotoxic co-medication (cyclosporine A, aminoglycosides, and ganciclovir), there was a median decline in serum creatinine clearance from 57 to 35 mL/min. One patient transiently required hemofiltration. However, renal function recovered after amphotericin B treatment had been stopped. [40]. The calculated creatinine clearance was retrospectively analysed in allogeneic hematopoietic stem cell recipients under immune-suppression with cyclosporine A on and off amphotericin B administered by continuous infusion. Creatinine clearance was 55 mL/min in patients on and 69 mL/min patients without amphotericin B treatment (P = 0.0002) [41]. Several case reports and observational studies advocate the administration of amphotericin B as a continuous infusion to enhance its tolerability [42‐44]. Quite different results were obtained by Maharom and Thamlikitkul from 148 patients undergoing 166 treatment courses. Amphotericin B had been administered by continuous infusion in 61.4%. Infusion-related toxicity was less frequent in patients on continuous infusion. Renal toxicity was also somewhat lower in this group, but the difference was not significant. Surprisingly, the mortality was significantly higher in patients on continuous infusion compared to those who had obtained intermittent infusions (T _inf 4–6 h) [44]. For explanation of these conflicting results, two effects on mortality have to be considered. First, renal failure is associated with an enhanced mortality. Improved renal tolerability of amphotericin B treatment by continuous might therefore results in a better survival. Second, the mortality of IFI will depend on the efficacy of fungal eradication, and as mentioned, the ratio C _max/MIC is supposed to correlate best with the antifungal activity of amphotericin B. For optimal efficacy against A. fumigatus, C _max/MIC >2.4 has been suggested [45]. From a pharmacodynamic point of view, intermittent administration might therefore be advantageous. Whether antifungal efficacy of amphotericin is adequate with continuous infusion remains to be clarified [37].

Nowadays, amphotericin B deoxycholate is contra-indicated in acute renal failure as less nephrotoxic antifungals are available. However, its use is possible in terminal renal failure requiring renal replacement therapy. Relatively small doses of 25–50 mg have been applied during intermittent hemodialysis three times per week. Since nephrotoxicity has no impact under this condition, the standard dosage appears to be appropriate in hemodialysis patients suffering from life-threatening fungal infections. Continuous veno-venous hemofiltration performed in two critically ill patients with terminal renal failure on amphotericin B deoxycholate treatment appeared to accelerate the amphotericin B clearance [46]. Recently, relatively low C _max and large V _d values were reported from critically ill patients [47].

Lipid encapsulation is another approach to improve tolerability of amphotericin B. Several preparations have been developed and assessed in preclinical and clinical studies. Three formulations with different chemical composition, particle size and shape have been launched: Liposomal amphotericin B (AmBisome^®, Gilead, Dublin, Ireland), amphotericin B colloidal dispersion (colloidal amphotericin B, Amphotec^®, Amphocil^®, Ben Venue Laboratories, Bedford, Ohio, USA), and amphotericin B lipid complex (Abelcet^®, Sigma-Tau Pharma Source, Inc., Indianapolis, IN). Today, liposomal amphotericin B is the only widely available lipid formulation. Liposomal amphotericin B consists of spherical uni-lamellar vesicles (liposomes) of 45–80 nm in diameter containing hydrogenated soy phosphatidylcholine, cholesterol, distearoyl phosphatidylglycerol, and amphotericin B in a molecular ratio of 2:1:0.8:0.4 [48]. The production of amphotericin B colloidal dispersion, a cholesteryl sulphate complex of amphotericin B, has been stopped in 2012 [49]. The lipid moiety of amphotericin B lipid complex consists of l-alpha-dimyrsitoylphosphatidylcholine, l-alpha-dimyrsitoylphosphatidylglycerol forming ribbon-like structures, 1600–11,000 nm in length [50].

The recommended standard doses of lipid-formulated amphotericin B are much higher than that of conventional amphotericin B: for liposomal amphotericin B, it is 3–4 mg/kg per day (5 mg/kg for mucormycosis, even 10 mg/kg, for Mucorales infections of the CNS). For amphotericin B lipid complex, the standard dose amounts to 5 mg/kg once daily. Amphotericin B lipid formulations display marked differences in their pharmacokinetics [36]. After repeated administration of 5 mg/kg/d of liposomal amphotericin B, amphotericin B peak levels as high as 90 µg/mL were measured [51‐53]. A t _1/2 of 5–10 h was determined in most of the studies (see Table 1). This is shorter than that observed during treatment with amphotericin B lipid complex. Liposomal amphotericin B has a relatively small volume of distribution of ~0.1–0.2 L/kg (see Table 1), that of amphotericin B lipid complex is highly variable and very large (up to 131 L/kg) [54, 55]. C _max values of 2 µg/mL are reached with amphotericin B lipid complex at standard doses. Liposomal amphotericin B and amphotericin B lipid complex display non-linear pharmacokinetics [32, 52, 54, 56]. Unlike lipid-encapsulated amphotericin B, the liberated fraction displayed quite similar pharmacokinetics after administration of different lipid formulations [46, 57].

In critically ill patients, lower amphotericin B plasma levels were achieved by liposomal amphotericin B than in healthy subjects or in less compromised patients [34, 46, 58]. Continuous veno-venous haemofiltration, haemodiafiltration and intermittent haemodialysis, did not significantly affect exposure to liposomal amphotericin B [34, 46, 58, 59]. CL and AUC_0–24 h of liberated amphotericin B which is looked upon as the active amphotericin B fraction were not significantly different on and off hemofiltration. Standard dosage is, therefore, probably adequate during continuous renal replacement therapy [46]. This is also true for amphotericin B colloidal dispersion and amphotericin B lipid complex [46, 60]. Amphotericin B lipid complex, however, should be avoided in patients with renal impairment because of its nephrotoxicity [54]. Cholestatic liver disease had no significant influence on steady state pharmacokinetics of liberated amphotericin B when amphotericin B colloidal dispersion was administered [61]. In three patients treated with albumin dialysis for cholestatic liver failure who received lipid-formulated amphotericin B (one patient liposomal amphotericin B, one amphotericin B colloidal dispersion and one patient amphotericin B lipid complex), exposure with liberated amphotericin B was slightly decreased. However, a dose adjustment of lipid-formulated amphotericin B for albumin dialysis is probably not necessary [62, 63]. In a patient on extracorporeal membrane oxygenation (ECMO), amphotericin B levels were measured 13 and 18 h after administration of liposomal amphotericin B at a dose of 3 mg/kg. Levels were within the therapeutic range with 5.8 and 6.2 µg/mL, respectively [64].

The antifungal activity of lipid-formulated amphotericin B at doses of 3–5 mg/kg is comparable to that of 0.6–1.0 mg/kg of amphotericin B deoxycholate [34, 50, 65‐77]. At these standard doses, the amphotericin B lipid formulations are less toxic than amphotericin B deoxycholate. The underlying mechanisms are not yet completely understood. Suggested explanations comprise targeting to fungal cell surface with minimal systemic exposure to free amphotericin B as well as different binding to plasma lipoproteins and rapid uptake by the reticuloendothelial system (RES) [67, 75, 77‐84]. However, considerable amounts of amphotericin B are liberated from lipid encapsulation in the plasma of healthy subjects and patients [28, 46, 57]. Reduced concentrations of free amphotericin B may probably play a role [36, 57].

Tissue penetration of amphotericin B was studied in human autopsy material of patients who had received amphotericin B deoxycholate. There was an accumulation of amphotericin B in liver and spleen. Concentrations were intermediate in lung and kidney and low in myocardium and brain [78, 85]. After treatment with amphotericin B lipid formulations, amphotericin B target-site distribution in autopsy samples was similar to that reported after amphotericin B deoxycholate with tissue levels of ~100 µg/g in the liver and lowest concentrations in myocardium and cerebral cortex (~1 µg/g) [86]. In a preclinical study, enhanced cerebral amphotericin B uptake was achieved by exposure to P-glycoprotein (P-gp) inhibitors verapamil and itraconazole [87]. In P-gp knock-out mice, however, brain concentrations of amphotericin B were low [88].

In pulmonary epithelial lining fluid (ELF), amphotericin B levels were much lower than those in whole lung tissue (~0.4–1.6 µg/mL) [89]. Even lower amphotericin B concentrations have been recovered from pleural effusion and from ascites during treatment with different amphotericin B formulations [90‐92]. Biliary excretion of amphotericin B appears to depend on the administered formulation. Biliary concentrations of ~5 and 41 µg/mL were achieved with amphotericin B deoxycholate therapy in a patient suffering from C. albicans cholecystitis and in a cancer patient, respectively. The C _max values in plasma were 1.1 and 1.64 µg/mL, respectively. In the cancer patient, switching to amphotericin lipid complex resulted in a biliary C _max of 60 µg/mL [93, 94]. More recently, biliary amphotericin B levels in liver transplant recipients on treatment with lipid-formulated amphotericin B were assessed. Biliary concentrations were much lower with a maximum of 1.28 µg/mL. In addition, bile displayed an inhibitory effect on antifungal activity of amphotericin B [95].

Flucytosine is available for oral and for intravenous administration. The standard dose recommended by the manufacturer is 100-150 mg/kg per day (25–37.5 mg/kg four times per day, T _inf = 30 min). Its oral bioavailability amounts to 76–89% [98]. Flucytosine is hydrophilic and has a low protein binding of 3–4% [99]. It is eliminated by about 90% via glomerular filtration with a t _1/2 of 3–4 h [99, 100]. A volume of distribution at steady state (V _ss) of 0.4–0.8 L/kg has been calculated in healthy volunteers. C _max values were 50–100 µg/mL, and C _min values were 25–50 µg/mL under this regimen (see Table 2) [97]. C _max > 100 µg/mL, and C _min < 25 µg/mL must be avoided.

The flucytosine plasma clearance resembles the creatinine clearance. Prolonged t _1/2 of up to 85 h has been observed in renal failure [101]. Accordingly, a prolonged dosage interval of 12 h (37.5–50.0 mg/kg b.i.d.) is recommended when creatinine clearance is 20–40 mL/min and of 24 h for a creatinine clearance of 10–20 mL/min (37.5–50.0 mg/kg once daily) [101].

As 5-flucytosine is efficiently eliminated via haemodialysis, it has to be applied after the dialysis sessions [99, 101‐103]. Because of its low protein binding and its small molecular weight, an efficient elimination via continuous renal replacement therapy has to be anticipated. The optimal dosage for patients with renal failure requiring continuous veno-venous haemofiltration or continuous veno-venous haemodialysis is not yet established. In an early study on seven patients on continuous arteriovenous or veno-venous haemofiltration, prolonged t _1/2 of 16–37 h were found after a single dose of 2.5 g. There was a linear relationship between ultrafiltration rate (16 mL/min on average) and 5-flucytosine elimination. The volume of distribution amounted to 0.77–0.98 L/kg. The authors recommended administration of 2.5 g with adaption of the dosage interval, e.g. 12 h for an ultrafiltration rate of 20 mL/min [104]. Thomson et al. measured an elevated C _max of 110 µg/mL after 3 days of treatment with 50 mg/kg per day. The estimated half-life and clearance were 37 h and 1.1 L/h, respectively. Therefore, they suggested a dose of 2.5 g every 48–72 h [105]. Recently, an 81-year-old patient (body weight 97 kg) was treated with 2.5 g of oral 5-flucytosine twice daily during continuous veno-venous haemofiltration using a contemporary protocol with an ultrafiltration rate of 2.5 L/h and a polyarlethersulfone membrane. This resulted in supra-therapeutic C _max and C _min were of 120 and 81 μg/mL, respectively, causing thrombocytopenia [106]. Even highly efficient continuous veno-venous haemodiafiltration with a dialysate flow rate of 1 L/h and an ultrafiltration rate of 2 L/h (blood flow rate 200 mL/h) did not normalise 5-flucytosine elimination. Under standard dose (25 mg/kg q.i.d. intravenously), C _max and C _min amounted to 120 and 74 µg/mL, respectively, t _1/2 was 12.6 h [107].

For patients with hepatic impairment, no reduction of the flucytosine dose is recommended, as flucytosine does not undergo significant hepatic biotransformation or biliary elimination [98, 103, 108, 109]. But its hepatotoxicity limits its use in this condition.

Pharmacokinetic drug–drug interactions involving the cytochrome P 450 system are a minor concern in flucytosine treatment. Nephrotoxic co-medication such as amphotericin B or cyclosporine A, however, can lead to enhanced flucytosine levels. The toxicity of 5-flucytosine, probably correlates with fluorouracil plasma concentrations. Fluorouracil is degraded by dihydropyrimidine dehydrogenase. Therefore, simultaneous treatment with flucytosine and inhibitors of dihydropyrimidine dehydrogenase such as nucleoside analogues, e.g. brivudin or sorivudine is contra-indicated. After cessation of brivudin or sorivudine flucytosine treatment must not be started within 4 weeks. In addition, pharmacodynamic drug–drug interactions have to be considered. The myelotoxic effects of antineoplastic and immunosuppressive medications are increased when flucytosine is applied. Cytarabine interferes with fungal flucytosine permease thus abolishing its antifungal activity [97]. Although not available in our institutions, we strongly advocate therapeutic drug monitoring of 5-flucytosine, in particular, when it is administered to patients with potentially altered pharmacokinetics.

Flucytosine displays a favourable penetration into various relevant compartments such as human CSF where 71–85% of the simultaneous serum concentrations are achieved. Relatively high levels were also measured in saliva (~50% of the respective serum levels), in ascites (~25–40% of the respective serum concentration), and in bronchial secretion (~76% of the respective serum concentration). Flucytosine kinetics in bronchial secretion was assessed in a dog model displaying almost constant levels of about 20 µg/mL over 3 h [110]. Even at the so-called sanctuary sites, considerable flucytosine concentrations were reached, e.g. 10 µg/mL in aqueous humour (20% of the serum level), 3 µg/mL in bone (30% of the respective serum level), and 26 µg/mL in synovial fluid (41% of the serum concentration). In peritoneal fluid, flucytosine levels were comparable to the simultaneous plasma levels [91]. Highest concentrations are measured in urine (~tenfold serum concentration) [108].

An oral dose of 200–400 mg once daily has been applied for the treatment of fungal infections. The oral bioavailability of ketoconazole is highly variable and dependent of oral nutrition and gastric pH. Its plasma protein binding amounts to 84%, 15% are bound to erythrocytes [101]. Ketoconazole is transformed in the liver into inactive metabolites by CYP3A4. Finally, it is eliminated via the bile. Ketoconazole is a strong inhibitor of P-gp and CYP3A4 causing numerous drug–drug interactions. Its elimination half-life (t _1/2β is ~2 h, the terminal half-life (t _1/2γ) amounts to 8 h. A favourable penetration into the urine, the saliva, the synovial fluid, into sebum and cerumen has been described [101].

Today, ketoconazole is used as a model drug for inhibition of CYP3A4 and P-gp in pharmacokinetic studies. Thus, enhanced plasma concentrations of cyclosporine A, clarithromycin, telithromycin, everolimus, antihistamines, rosiglitazone, midazolam, isavuconazole, riociguat, drospirenone, tetrahydrocannabinol, and cannabidiol were measured during concomitant administration of ketoconazole [113‐123].

Ketoconazole also inhibits corticosteroid synthesis [124]. Today, systemic ketoconazole as a tablet form (Ketoconazole HRA, Laboratoire HRA Pharma, Paris, France) is therefore licensed for medical treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. Maintenance doses required for this indication range from 400 to 1200 mg per day taken orally in two to three divided doses to restore normal cortisol levels. As ketoconazole also inhibits testosterone synthesis, it has been used in androgen independent prostate cancer [125].

The therapeutic dose of fluconazole is guided by the indication. For patients in with invasive candidiasis in stable condition, recent guidelines recommend a loading dose of 12 mg/kg (800 mg) followed by a maintenance dose of 6 mg/kg (400 mg) once daily administered by intravenous infusion [12]. Lower oral doses are sufficient for uncomplicated skin, mucosal or urinary tract infections. After oral administration, fluconazole is well absorbed [bioavailability (F) >90%]. Food intake, gastric pH, and gastro-intestinal surgery had no major influence on enteral fluconazole absorption [128‐130]. In healthy volunteers, intake of 400 mg of fluconazole led to a C _max of 9.1 µg/mL. A C _max of 1.7 µg/mL and an AUC_0−∞ of 93 µg h/mL were measured after an oral dose of 100 mg. T _max amounted to 0.5–1.0 h. Fluconazole has a plasma protein binding of ~12%, and a t _1/2 of ~30 h [129]. Thus, it takes 6 days to achieve steady state concentrations unless a loading dose is applied. The total fluconazole CL in healthy volunteers was 15–24 mL/h/kg [114, 130‐132] and the apparent volume of distribution at steady state (V _ss) was about 0.75 L/kg [132, 133]. Fluconazole is eliminated via the kidney by 60 to 80% where it undergoes glomerular filtration and tubular re-absorption (see Table 3).

Hepatic metabolism does not play a role in fluconazole elimination. But fluconazole is a strong inhibitor CYP3A4 and CYP2C9. Numerous drug–drug interactions must therefore be considered [113, 129]. Simultaneous treatment with CYP3A4 and CYP2C9 substrates should therefore be avoided, in particular with those prolonging the QT interval [133‐135]. Cyclosporine A, tacrolimus or sirolimus are substrates of CYP3A4. Transplant recipients on immunosuppression with one of these drugs are therefore at a high risk of adverse effects, e.g. nephrotoxicity or over-immunosuppression. Dose reduction and close therapeutic drug monitoring of these immunosuppressives is mandatory when the combination with fluconazole is thought to be indispensable [136‐144]. Combination of fluconazole with warfarin prolongs the prothrombin time and can cause severe bleedings [145, 146]. Fluconazole inhibits phenytoin metabolism via CYP2C bearing the risk hepatic and neurological adverse effects [147‐149]. C _max and AUC_0−∞ values of tolbutamide were enhanced by fluconazole causing hypoglycaemia [150]. C _max of celecoxib, which has affinity to CYP2C9, increased by 60% and the AUC by 130%. A markedly prolonged sedative effect of midazolam and triazolam has to be anticipated in combination with fluconazole [113, 151]. The levels of levonorgestrel and ethinyl estradiol were moderately enhanced by 40 and 24%, respectively, under fluconazole treatment. Although fluconazole is mainly eliminated via the kidney, CYP3A induction by rifampin can decrease fluconazole exposure bearing the risk of treatment failure [152, 153]. The metabolism of rifabutin appears to be inhibited by fluconazole [154].

For critically ill patients, doses of 800–1200 mg per day resulting in C _max values of 40–60 µg/mL have been proposed [155]. This is supported by the observation of an impaired target-site penetration in septic patients [156]. In 15 critically ill patients treated with fluconazole at a median dose of 4.9 (2.3–5.0) mg/kg, concentrations were highly variable and five patients did not reach the pharmacokinetic/pharmacodynamic target defined as a ratio between AUC_0–24 h (free drug) and MIC of 100 or greater (fAUC_0–24h/MIC ≥100) [157]. For obese critically ill patients, fluconazole dosage according to the actual body weight (loading dose 12 mg/kg, maintenance dose 6 mg/kg per day) has recently been proposed. This recommendation is based on a pharmacokinetic study of 21 patients. Six patients were obese with a body mass index of 30.0–39.9 kg/m²; four patients were morbidly obese with body mass index ≥40 kg/m² [158]. In extremely premature infants with a birth weight <750 g, intravenous or oral administration of 6 mg/kg twice weekly appears to be adequate [159].

For patients with renal failure, a reduction of the fluconazole maintenance dose is necessary because of delayed elimination. A prolonged t _1/2 of 96 h and a 50-percent decrease in fluconazole CL (~10 mL/h/kg) were determined in renal failure with a creatinine clearance of 35 mL/min [132]. Accordingly, the dose of fluconazole should be reduced by 50% in patients with a creatinine clearance of 11–50 mL/min. High amounts of fluconazole are eliminated by renal replacement therapy. Its plasma concentration was decreased by ~40% during a 4-h haemodialysis session [160]. During continuous ambulatory peritoneal dialysis, t _½ was 79 h, and CL was 8 mL/kg/h, which are values comparable to those obtained in patients with a creatinine clearance of 35 mL/min [131, 161]. Continuous renal replacement therapy such as continuous veno-venous hemofiltration and haemodiafiltration is highly efficient in fluconazole elimination. This is explained by the low protein binding, the high water solubility, the relatively small molecular weight of fluconazole, and by the lack of tubular re-absorption in patients with renal failure. During haemodiafiltration a mean C _max of 26 µg/mL, a very short t _1/2 of only 9 h, and a high CL of 60 mL/h/kg were determined after infusion of 800 mg of fluconazole over 2 h. Based on these data, 500–600 mg twice daily have been suggested for patients on haemodiafiltration [162]. For continuous veno-venous haemofiltration, an intravenous dose of 800 mg once daily has been recommended [163]. Critically ill patients on prolonged intermittent renal replacement therapy appear to require a loading dose of 800 mg of fluconazole followed by 400 mg twice daily (before and after prolonged intermittent renal replacement therapy) for treatment of infections with susceptible C. albicans [164]. In a patient on sustained low-efficiency diafiltration, fluconazole kinetics was determined in plasma and subcutaneous interstitial fluid using microdialysis technique. Fluconazole rapidly penetrated into subcutaneous interstitial fluid [165].

During treatment with ECMO, V _d of fluconazole was enhanced in children. Based on population modelling, the authors suggest treatment with an enhanced loading dose of 35 mg/kg followed by standard maintenance dose [166].

Animal studies on rabbits and rats revealed relatively high fluconazole tissue concentrations [113, 167, 168]. Fluconazole concentrations in urine, in blister fluid, in blister roof, in skin scrapings, in vaginal mucosa, in saliva, in sputum and in CSF were assessed in early clinical studies. The highest fluconazole concentrations were measured in urine and in skin exceeding plasma levels. In most of the tissues, fluconazole concentrations were similar to the simultaneous plasma concentrations, e.g. in CSF, 50–90% of the respective plasma levels [169‐171]. In human brain samples obtained from tumour surgery, Thaler et al. measured a mean fluconazole concentration of 17.6 µg/g (133% of the respective plasma level) [172]. Sinnollareddy et al. found a variable target-site penetration of fluconazole in critically ill patients with sepsis. In subcutaneous interstitial fluid, AUC_0–24 h was about 50% lower than the AUC_0–24 h in plasma [156]. In ascites of a liver transplant recipient treated with fluconazole for 5 days (loading dose 400 mg, maintenance dose 150 mg per day, serum creatinine 1.7 mg/dL), C _min amounted to 9.6 µg/mL (85% of the simultaneous plasma level). Biliary C _min values of 9.0 and 6.3 µg/mL (~50% of C _min in plasma) were measured in two other liver transplant recipients [173]. Biliary concentrations of up to 14 µg/mL were reached by intravenous or oral administration of 200 mg of fluconazole per day (serum creatinine 2.8 mg/dL) [174].

The oral dose of itraconazole recommended by the manufacturer for systemic mycoses is 200 mg once daily or b.i.d. The intravenous formulation is not widely available. The recommended intravenous dose is 200 mg b.i.d. for the first 2 days followed by 200 mg once daily. Because of potential nephrotoxicity of the solvent vehicle hydroxypropyl-β-cyclodextrin the manufacturer recommends early switch to oral treatment with 200 mg b.i.d., e.g. after 5 days if enteral absorption can be anticipated. Absorption of oral itraconazole amounts to ~55%, but is highly variable and depending on food intake, when the capsule formulation is used. It may be decreased by infections and other co-morbidities [185‐190]. Absorption of the oral suspension which contains hydroxypropyl-β-cyclodextrin is better without food intake, and it is superior to that of the capsule formulation [191, 192]. The intravenous itraconazole formulation contains also hydroxypropyl-β-cyclodextrin. At steady state, itraconazole has a t _1/2 of ~30 h. The T _max is 5 h, the plasma protein binding is as high as 99.8%, V _d is large (11 L/kg) [36]. Itraconazole undergoes excessive hepatic metabolism involving CYP3A4. The most active metabolite is hydroxy-itraconazole. Fifty-four percent of the administered dose are eliminated via the faeces, 35% via the urine after metabolism (see Table 4). The majority of metabolites are inactive [185, 193, 194]. As itraconazole absorption is highly variable and exposure is difficult to predict, therapeutic drug monitoring will be indispensable for the treatment of systemic infections in the majority of cases [195].

As itraconazole is a strong inhibitor of CYP3A4, a long list of drug–drug interactions has to be considered. Co-administration of itraconazole with lovastatin, atorvastatin, simvastatin, or quinidine is contra-indicated. Plasma levels of many other CYP3A4 substrates such as midazolam, triazolam, cyclosporine A, tacrolimus, sirolimus and everolimus, methylprednisolone, warfarin, digoxin, carbamazepine, rifabutin, and anti-retroviral drugs such as ritonavir, indinavir, and saquinavir will increase when itraconazole treatment is started in patients on treatment with one of these drugs [113, 196]. Co-administration of negative inotropic drugs may enhance the risk of congestive heart failure, and plasma levels of calcium antagonists are enhanced by itraconazole [175, 197‐199]. In vitro, itraconazole has also a strong inhibitory potential on the ATP-binding cassette transporters P-gp, breast cancer related peptide (BCRP), and bile salt export pump (BSEP, ATP-binding cassette protein B11 or ABCB11). P-gp is also inhibited by the metabolite hydroxy-itraconazole [200].

For critically ill patients, intravenous infusion for 7 days, followed by oral administration has been proposed [201]. Itraconazole is not eliminated by intermittent hemodialysis. Surprisingly, continuous haemodiafiltration resulted in increased itraconazole elimination. Doses exceeding 300 mg t.i.d. may be required [191, 202].

In the skin and in fat, the highest itraconazole concentrations were measured exceeding the simultaneous plasma concentrations 19-fold and 17-fold, respectively. In liver, in lung, particularly in alveolar macrophages, in kidney, spleen, bone, and in muscle, concentrations were above the plasma levels [191, 203].

The recommended intravenous standard dose is 6 mg/kg b.i.d. on day 1 (loading dose) followed by 4 mg/kg b.i.d. (maintenance dose). The oral dose for adult patients is 400 mg b.i.d. on day 1 followed by 200 mg b.i.d. For adult patients with a body weight of less than 40 kg, a dose reduction by 50% is recommended (loading dose, 200 mg b.i.d maintenance dose, 100 mg b.i.d.). In healthy volunteers, the bioavailability of voriconazole amounts to 96% and is independent from gastric pH, but may be considerably lower in patients. Voriconazole displays non-linear pharmacokinetics. After treatment with oral standard dose, a C _max of 2 µg/mL and a C _min of 0.5 µg/mL were measured on day 7. An increase of the dose by a factor of 1.7 led to a 2.4-fold elevation of C _max and a 3.1-fold increase of the AUC over the dosage interval (AUC _τ ) [36, 208, 209]. C _max is usually reached 1.5–3 h after oral intake. After administration of the recommended intravenous dose, C _max and AUC _τ amounted to 4.4 µg/mL and 29.5 µg h/mL, respectively, in male healthy volunteers [210]. The plasma protein binding of voriconazole amounts to 58% which is markedly lower than that of all the other azoles but fluconazole. The V _d of voriconazole is ~4.5 L/kg, and CL ~7 L/h (~100 mL/h/kg) in healthy volunteers. Voriconazole undergoes hepatic phase I biotransformation involving CYP2C9, CYP2C19, and CYP3A4. Rate-limiting is the fluoropyrimidine-N-oxidation. As there is a genetic polymorphism of CYP2C9, there are ultra-rapid and poor voriconazole metabolizers. A fourfold elevation in plasma levels has been found in the latter population. In Asians, a prevalence of slow voriconazole metabolizers of ~20% has been reported [208, 209]. Inactive metabolites of voriconazole are eliminated by ~80% via the urine and by ~20% via the faeces (see Table 3) [209, 210]. On average, t _1/2 of voriconazole is ~6 h at standard dosage, but it increases with the plasma concentration.

Voriconazole is a strong inhibitor of CYP2C19, CYP2C9 and a moderate inhibitor of CYP3A4. It is also a substrate for CYP2C19, CYP2C9 and CYP3A4. Therefore, numerous potentially dangerous drug–drug interactions have to be anticipated during treatment with voriconazole. Inhibition of the metabolism of immune-suppressants causing enhanced exposure can be particularly harmful. Therefore, the doses of cyclosporine A and of tacrolimus have to be reduced by 50 and 66%, respectively, when voriconazole treatment is initiated. Close therapeutic drug monitoring of immune-suppressants is indispensable to avoid excessive immunosuppression and renal damage. Voriconazole has been shown to enhance C _max and AUC _τ of sirolimus by 556 and 1014%, respectively. Concomitant use of sirolimus and voriconazole is therefore contra-indicated [211]. Enhanced plasma concentrations of vitamin K antagonists and probably of direct acting oral anticoagulants by voriconazole bear the risk of severe haemorrhage. The sedative effect of benzodiazepines is prolonged by voriconazole. This is also true for the combination with the opioids fentanyl, alfentanil, oxycodone and methadone. In patients on sulfonylureas, voriconazole treatment may cause hypoglycaemia. Statin levels can be enhanced by voriconazole bearing the risk of rhabdomyolysis. We therefore recommend discontinuation of statin therapy as long as voriconazole is administered. For omeprazole, a dose reduction by 50% is advised when voriconazole is concomitantly used. Accumulation of histamine blockers (e.g. terfenadine and astemizole), cimetidine or quinidine under voriconazole treatment is particularly dangerous, because of an additional pharmacodynamic drug–drug interaction. These drugs, just as voriconazole, may cause prolongation of the QT interval resulting in torsades de pointes [212]. Impaired efficacy of voriconazole because of sub-therapeutic plasma levels is caused by co-administration of CYP inducers such as rifampicin or carbamazepine. An enhanced voriconazole dosage of 5 mg/kg i.v. or 350 mg p.o. b.i.d. has been recommended, when the combination of voriconazole and rifabutin appears to be indispensable [211]. Combination with the HIV protease inhibitors saquinavir, amprenavir and nelfinavir may enhance exposure to these drugs and to voriconazole [211]. The non-nucleoside HIV reverse transcriptase inhibitors delavirdine and efavirenz also cause elevated voriconazole levels [208, 211, 213]. Intake of St. John ´s wort will lower voriconazole levels [214].

For children (2–11 years old) and for young adolescents with low body weight (12–14 years old, body weight <50 kg), the manufacturers recommend a loading dose of 9 mg/kg every 12 h on day 1, followed by an intravenous maintenance dose of 8 mg/kg twice daily. Oral administration of a maintenance dose 9 mg/kg twice daily (maximum dose of 350 mg b.i.d.) can be considered, but a 50-percent decrease in voriconazole exposure has to be anticipated with the oral regimen. In lung transplant recipients, the absorption of voriconazole is significantly decreased with a bioavailability of only 24–63% [215]. In patients with mild or moderate liver cirrhosis (stage Child–Pugh A and B) voriconazole metabolism is impaired and CL is delayed by ~50%. Therefore, the maintenance dose should be reduced by 50% [208]. Severe liver disease (e.g. liver cirrhosis Child–Pugh stage C), may result in prolongation of t _½ by ~tenfold [216, 217]. Drug monitoring is essential in this condition.

Renal impairment at any stage appears to have no relevant influence on voriconazole pharmacokinetics, and does not require dose adjustment for the oral voriconazole preparations [208]. However, a considerable accumulation of the solvent vehicle SBECD was observed in patients with impaired renal function undergoing intravenous voriconazole treatment [208]. SBECD the solubiliser of the intravenous voriconazole preparation is a large cyclic oligosaccharide which is potentially nephrotoxic at higher concentrations. Therefore, the manufacturer advises to prefer oral voriconazole in patients with a creatinine CL <50 mL/min.

In a patient on continuous veno-venous haemodiafiltration, voriconazole pharmacokinetics was reported to be similar to that in patients off haemodiafiltration. The extracorporeal CL by haemodiafiltration was <10% of the total CL [218]. In nine critically ill patients undergoing continuous veno-venous haemodiafiltration, mean C _max and C _min were 5.9 and 1.1 mg/L, respectively, after a single intravenous 6-mg dose. A mean AUC_0–12 h of 22.4 µg h/mL, a V _d of 228 L, a t _1/2 of 14.7 h, a sieving coefficient of 0.56, and mean total CL of 12.9 L/h were reported. The extracorporeal CL via continuous veno-venous haemodiafiltration was ~1 L/h. Despite an enlarged V _d, a prolonged t _½ and an increased total CL, the voriconazole exposure was similar to that in healthy subjects, and no dose adjustment was recommended for patients on continuous veno-venous haemodiafiltration [217]. From six patients on continuous veno-venous hemofiltration, a similar C _max value (mean 4.3 µg/mL) and a somewhat higher voriconazole exposure (mean AUC_0–12 h, 53.5 µg h/mL) were reported. The mean sieving coefficient was lower (0.22), and t _1/2 was longer (27.6 h). Because of a considerable variability in plasma levels, the authors recommend therapeutic drug monitoring [219]. In a more recent study of ten critically ill patients on continuous veno-venous haemofiltration, the latter findings were confirmed: mean C _max was 4.1 µg/mL, C _min 2.4 mg/L, t _1/2 19.5 h, and the mean AUC_0–12 h was 37 µg h/mL [220]. In a single patient on high-volume continuous veno-venous hemofiltration, a somewhat higher voriconazole exposure was observed despite an efficient extracorporeal CL of voriconazole (AUC_0–12 h, 65 mg h/L, total CL, 5.4 L/h, t _1/2, 16.5 h, V _d, 128.6 L, sieving coefficient, 0.58, extracorporeal CL, 1.4 L/h). This was ascribed to impaired hepatic metabolism because of multi-organ failure [221].

The effects of different renal replacement techniques on SBECD kinetics have also been investigated. Not surprisingly, continuous renal replacement therapy was more efficient in SBECD elimination than intermittent. As long as information on safety of SBECD is insufficient, alternatives for intravenous voriconazole should be considered in patients with renal impairment. Oral administration with therapeutic drug monitoring could be an option in stable conditions, intradialytic administration in terminal renal failure. In patients on continuous renal replacement therapy, administration of the intravenous voriconazole preparation appears to be safe [220, 222, 223].

During veno-arterial ECMO, voriconazole levels were low or even undetectable, whereas therapeutic concentrations where achieved by an enhanced dose in a patient on veno-venous ECMO [64, 224].

Given the complex pharmacokinetics and metabolism, the variable absorption and the numerous drug–drug interactions, therapeutic drug monitoring has a paramount role in voriconazole treatment to warrant sufficient dosage and therapeutic safety [195, 225].

Voriconazole displayed high tissue penetration in animal models [208, 226]. In human autopsy samples, median voriconazole concentrations amounted to 3.41 µg/g in the brain, 6.26 µg/g in the lung, 6.89 µg/g in the liver, 5.60 µg/g in the spleen, 6.47 µg/g in the kidneys, and 7.55 µg/g in myocardium [227]. In CSF, variable voriconazole concentrations have been measured. In samples obtained by lumbar puncture, the median concentration amounted to 0.65 µg/mL [penetration ratio, 0.46 (range 0.22–1.00)] [226]. When CSF was taken from ventricular drainage, lower levels of 0.08–0.17 µg/mL were found [228]. Voriconazole kinetics in pulmonary ELF were assessed in 20 healthy volunteers who had received the intravenous standard dose for 3 days. Sampling of ELF and blood was performed 4, 8, 12, or 24 h after start of voriconazole administration (n was 5 for each time point, T _inf, 2 h). In plasma, mean C _max, t _1/2, and AUC _τ were 5.3 mg/mL, 6.9 h, and 39.5 µg h/mL, respectively. In ELF, mean C _max amounted to 48.3 µg/mL, and in alveolar macrophages 20.6 µg/mL. The AUC_τ values calculated for ELF and alveolar macrophages were 282 and 178 µg h/mL, respectively. The penetration ratio for ELF (expressed by AUC_τ in ELF/AUC _τ in plasma) amounted to 7.1. For alveolar macrophages it was 4.5 (AUC _τ in alveolar macrophages/AUC _τ in plasma). [229]. In a study of 12 lung transplant recipients on voriconazole, single ELF and plasma samples were obtained at different times after oral intake. Concentrations in ELF amounted to 0.29–83.32 µg/mL. The estimated T _max in ELF was ~6 h. The penetration ratio (C in ELF/C in plasma) was 11 + 8 (mean + standard deviation) in this study population [230]. Voriconazole could also be recovered from pleural empyema. The concentrations amounted to 0.8–1.4 µg/mL, the penetration ratio (C in empyema/C in plasma) 0.45–0.95 [231].

For a decade, posaconazole had been available only as an oral suspension displaying poor and highly variable absorption [237‐241]. For this suspension, splitting of the therapeutic dose of 800 mg/d resulted in enhanced posaconazole exposure, because of saturable enteral absorption [237, 242]. Therefore, a therapeutic dose of 200 mg q.i.d and a prophylactic dose of 200 mg t.i.d. had been recommended for this formulation [237, 242]. Intake of fatty nutrition or nutritional supplements is necessary to warrant adequate absorption with this preparation [237‐239]. This was a particular challenge in patients undergoing myeloablative chemotherapy or in stem cell transplant recipients suffering from graft versus host disease. After a single dose of 400 mg, t _1/2 was ~20 h, C _max was 0.6 µg/mL, T _max 6.3 h, and the AUC_0−∞ was 19.4 µg h/mL [2, 239] (see Table 4).

Recently, an intravenous formulation and a tablet formulation with improved bioavailability have been launched. The gastro-resistant 100-mg-tablets comprise hypromellose acetate succinate and croscarmellose sodium. In a phase I study, oral intake of 100 mg of posaconazole in different tablet and capsule formulations including the currently available tablet form led to C _max, AUC_0–168 h, and AUC_0–∞ values that were more than three times above the respective values achieved by the same dose of the oral posaconazole suspension (median C _max, ~0.35 versus 0.08 µg/mL, median AUC_0–∞, 11 versus 3 µg h/mL). Notably, the median V _d was 1450 L after administration of the suspension and only 340 L after tablet intake. A slightly shorter t _1/2 was found in the tablet groups (~25 versus ~29 h), whereas CL was much slower for the tablet form (~9 versus ~34 L/h) [243]. C _max, AUC_0–∞ and AUC_0–last achieved by the tablet form were largely uninfluenced by co-medication affecting gastric pH and motility [244]. Doses of 200 and 400 mg were compared in a further phase I study after a single administration and at steady state [245]. On day 14, the mean C _max amounted to 1.8 and 2.9 µg/mL, and AUC_0–24h values were 31 and 57 µg h/mL after tablet intake at daily doses of 200 and 400 mg, respectively. Similar results were obtained from 50 patients with haematological malignancies, where the median C _max amounted to 2.1 µg/mL, and the median CL was 9.4 L/h [246]. The plasma protein binding of posaconazole amounts to 98–99% [239] (see Table 4). Intake of the tablets together with a fat-rich meal enhanced the AUC_0–72 h by 50% [247].

The concentrate for solution (300 mg per vial) for infusion contains Betadex sulfobutylether sodium (SBECD) as a solubiliser. The infusion should be applied via a central venous line to avoid thrombophlebitis. T _inf should be 90 min. Pharmacokinetics of the intravenous posaconazole formulation have been assessed in patients on myeloablative chemotherapy for haematologic malignancies [248]. After a single intravenous 300-mg dose, mean C _max and AUC_0–24 h amounted to 1.6 µg/mL and 8.2 µg h/mL, respectively. On day 14 of treatment with 300 mg once daily (loading dose 300 mg b.i.d.), a median C _max of 2.6 µg/mL, an AUC_0–24 h of 34 µg h/mL, a C _min of 1.1 µg/mL, and an accumulation ratio of 2.8 were determined. The recommended standard dose for the tablet and the intravenous formulation is 300 mg b.i.d. on day 1 followed by 300 mg once daily (see Table 4).

Posaconazole is glucuronidated in the liver by UDP-glucuronyl-transferase (UGT) 1A4. Inactive mono- and diglucuronides are formed. After intake of radiolabelled posaconazole as an oral suspension, 77% of the administered dose was recovered from the faeces, where the unchanged parent drug accounted for 66%. Only 14% of the applied radioactivity was detected in the urine, almost exclusively as glucuronides [2].

CYP isoenzymes have no relevant role in posaconazole disposition. However, posaconazole is a strong inhibitor of CYP3A4 causing numerous drug–drug interactions, e.g. increased levels of tacrolimus (2.2-fold C _max, and 4.5-fold AUC), of cyclosporine A, of glipizide, and of midazolam [237, 249]. Recently, it has been demonstrated that CYP3A4 inhibition is more pronounced when the tablet form is applied. For sirolimus, administration of 60% of the standard dose every third day has been proposed when it is combined with posaconazole [250]. The manufacturer advises against concomitant treatment with sirolimus and posaconazole, and recommends dose reduction for cyclosporin A, and for tacrolimus as well as close drug monitoring. Levels of simvastatin, atorvastatin, ergot alkaloids, vinca alkaloids, HIV protease inhibitors, midazolam, and verapamil are also enhanced by posaconazole. Recently, posaconazole has been reported to be a strong inhibitor of P-gp and BCRP in vitro [200].

Posaconazole is also a substrate for P-gp. Therefore, its plasma concentrations are enhanced by concomitant use of P-gp inhibitors such as verapamil, cyclosporine A, quinidine, clarithromycin, and erythromycin. Rifabutin, efavirenz, fosamprenavir, and phenytoin decrease posaconazole levels [249, 251, 252].

Therapeutic drug monitoring has been mandatory in patients on treatment or prophylaxis with the oral posaconazole suspension to warrant therapeutic levels [253, 254]. Target trough concentrations ≥ 1.0 and 0.7 µg/mL have been suggested for treatment and prophylaxis, respectively [255]. Although exposure is probably less variable with the new formulations, therapeutic drug monitoring is still advocated [256].

In a study of critically ill patients, the majority presented sub-therapeutic posaconazole plasma levels during treatment with standard doses of the oral suspension [257]. Mild to moderate renal or hepatic impairment had no relevant influence on posaconazole pharmacokinetics. In elderly (≥65 years), the AUC was enhanced by 29–42%. Thus, the manufacturer recommends standard dose for the latter conditions. Posaconazole is not removed by haemodialysis and in patients with terminal renal failure, posaconazole exposure on and off haemodialysis was almost identical [241, 251]. However, the manufacturer advises against the intravenous formulation in patients with moderate or severe renal impairment because of accumulation of the intravenous vehicle SBECD. There is one case report on the use of intravenous posaconazole during continuous veno-venous haemofiltration. A C _max of 2.8 µg/mL and a C _min of 1.7 µg/mL were measured. Thus, concentrations were comparable with those reported from patients off haemofiltration. Although SBECD exposure was 2.5 times higher than that in healthy volunteers, the authors do not anticipate relevant toxic effects [258].

Pulmonary target-site pharmacokinetics of posaconazole was investigated in two clinical studies on alveolar ELF. Posaconazole was administered as an oral suspension at a dose of 400 mg b.i.d. In the first study, 25 healthy adults were enrolled. Comparable posaconazole concentrations were measured in ELF and in the plasma (mean C _max 1.9 and 2.1 µg/mL, respectively). Posaconazole accumulated in alveolar cells (mean C _max 87.7 µg/mL) [259]. In a second study of 20 lung transplant recipients by the same authors group, posaconazole concentration were slightly lower: C _max was 1.3 µg/mL in ELF, 1.3 µg/mL in plasma, and 55.4 µg/mL in alveolar cells [260]. During the perioperative period, highly variable levels were measured in bronchoalveolar lavage fluid of transplant recipients on prophylaxis with posaconazole oral suspension [261].

In autopsy samples obtained from stem cell transplant recipients who had been on treatment with low doses, the highest posaconazole tissue levels have been recovered from the liver (up to 7.5 µg/g), followed by kidney (up to 4.6 µg/g), lung (up to 4.6 µg/g), myocardium (up to 1.8 µg/g), and brain (maximum 0.3 µg/g) [258, 262]. Lung concentrations exceeding the respective blood levels were recently determined in a rat model [263].

Posaconazole concentrations achieved in CSF were low (1.2–4.6 ng/mL) or even undetectable [264‐266]. In brain abscess fluid and CSF, respectively, of two patients with severe encephalitis and obvious disturbance of the blood brain barrier, concentrations of ~0.2 µg/mL could be achieved by administration of the oral suspension [266]. In muscle of a burn patient on continuous haemodialysis treated with standard doses of the oral suspension, posaconazole levels were below 0.1 µg/mL, probably because of poor absorption [267]. In vitro, fluorophore-labelled posaconazole accumulated in host and fungal cell membranes [268, 269].

Isavuconazonium sulphate is available for intravenous and for oral administration. There is a powder for concentrate for solution for infusion (200 mg isavuconazole as 372.6 mg isavuconazonium sulphate per vial), and there are hard capsules containing 100 mg of isavuconazole, equivalent to 186 mg of isavuconazonium sulphate. Because of the water solubility of isavuconazonium sulphate, no solvent is required for the intravenous formulation. As the oral bioavailability amounts to 98%, the intravenous and the oral dose are identical. Treatment has to be started with a loading dose of 200 mg three times per day applied for 2 days. The maintenance dose amounts to 200 mg once daily given as a 1-h infusion (one vial diluted to 0.8 mg/mL) or orally (two capsules) with or without food. Isavuconazole has a high plasma protein binding of 98–99%. Its volume of distribution amounts to 300–500 L, T _max is about 2 h after oral intake [274]. In male healthy volunteers, mean C _max values at steady state were 2.61 and 2.55 µg/mL after oral and intravenous administration, respectively. A single 200-mg loading dose followed by 100 mg once daily over 14 days had been applied. The mean AUC_0–24 h amounted to 41.5 and 33.6 mg h/L, respectively [274]. After single oral doses of 100–400 mg and intravenous doses of 50–200 mg, there was a linear increase of AUC with the dose [275]. Isavuconazole undergoes hepatic metabolism involving CYP3A4, CYP3A5, and subsequently UGT. Urinary excretion of unchanged isavuconazole is minimal with 0.02–0.04 and 0.06–0.38% of the administered dose after oral intake and after infusion, respectively. Equal amounts of the metabolites are excreted via urine and faeces. Isavuconazole has a long t _1/2 of about 80–120 h. The systemic CL was between 1.9 and 5.0 L/h in healthy volunteers [274, 275]. A population pharmacokinetic analysis was performed using data from nine phase 1 studies and one phase III study. The mean isavuconazole CL was 2.36 L/h (see Table 3). In Asians, it was 36% lower than in Caucasians [276]. This observation, however, was not confirmed in patients suffering from infections with filamentous fungi [277]. The mean AUC_0–24 h amounted to 92 µg h/mL in healthy volunteers, and to 101 µg h/mL in patients with IFI. Pharmacokinetic/pharmacodynamic modelling showed that the treatment with isavuconazole at standard doses is effective against Aspergillus strains with MIC values ≤0.5 µg/mL according Clinical and Laboratory Standards Institute (CLSI) methodology and ≤1 µg/mL according European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology [276].

As isavuconazole is a moderate CYP3A4 inhibitor, numerous drug–drug interactions have to be considered. Enhanced plasma levels of cyclosporine A, tacrolimus, sirolimus, and mycophenolate mofetil have to be anticipated, when isavuconazole is co-administered. The AUC_0–∞ of tacrolimus was enhance by 125% that of sirolimus by 84%, and that of cyclosporine A and mycophenolic acid by 29 and 35%, respectively [278]. Dose reduction and close therapeutic drug monitoring is strongly advised whenever isavuconazole is applied together with immunosuppressants. This is also true for the combination with digoxin. The pharmacokinetic effects of isavuconazole on colchicine and dabigatran appear to be less pronounced, but a dose reduction may be required. If the combination with midazolam or atorvastatin is indispensable, close monitoring is necessary [279]. Recently, isavuconazole did not have a clinically significant effect on warfarin pharmacokinetics in a phase I study of 20 healthy males [280]. An increase of isavuconazole levels has to be considered under treatment with lopinavir and ritonavir. Concomitant therapy with rifampin, carbamazepine, barbiturates or St John’s wort is contra-indicated because of resulting sub-therapeutic isavuconazole levels. A decrease in plasma levels of bupropion, lopinavir and ritonavir by isavuconazole has been reported [279]. Along with CYP3A4/5-mediated drug–drug interactions, effects on drug transporters might play a role. A recent in vitro study revealed considerable inhibition of the ATP-binding cassette transporters P-gp and BCRP by isavuconazole [200].

In a phase III study (“SECURE study”), moderate to severe renal dysfunction (calculated creatinine clearance <50 mL/min) was an exclusion criterion [272]. In patients suffering from infections with various moulds, dimorphic fungi, and non-Candida yeasts, population pharmacokinetics isavuconazole has been analysed. The estimated glomerular filtration rate did not correlate with the isavuconazole CL [277]. Mild, moderate and severe renal impairment did not influence isavuconazole pharmacokinetics. No relevant extracorporeal isavuconazole CL took place during intermittent haemodialysis and isavuconazole exposure remained largely unchanged. The investigators conclude that probably no dose adjustment is required for patients with end-stage renal disease undergoing intermittent haemodialysis [281]. The manufacturer recommends standard dosage for patients suffering from renal failure including those with end-stage renal disease. The effect of continuous renal replacement therapy on isavuconazole elimination, however, has not yet been assessed.

The impact of impaired liver function on isavuconazole pharmacokinetics has been assessed in patients with mild (Child–Pugh Class A) or moderate (Child–Pugh Class B) alcoholic liver cirrhosis who had received a single oral or intravenous dose of 100 mg. There was a significant increase in isavuconazole exposure in patients with hepatic dysfunction compared to healthy volunteers. After intravenous infusion of 100 mg of isavuconazole, the mean values for AUC_0–∞ were 0.039, 0.072, and 0.101 µg h/mL for normal, mildly impaired, and moderately impaired liver function, respectively. Half-lives amounted to 123, 224 and 302 h, respectively, and CL values were 2.13, 1.93 and 1.43 L/h for normal, mildly and moderately impaired liver function, respectively. Very similar values were obtained after oral isavuconazole intake [282]. A recently published population pharmacokinetic analysis revealed a mean isavuconazole CL of 1.55 L/h in patients with mild or moderate liver impairment, and a CL of 2.5 L/h in healthy volunteers. Simulations showed mean trough concentrations at steady state of 3.5, 5.3, and 6.1 µg/mL for normal, mildly impaired and moderately impaired liver function, respectively. Thus, there was a less than twofold increase in trough concentrations for subjects with mild and moderate hepatic impairment in comparison with healthy subjects [283]. Based on these data, the manufacturer recommends standard dose for patients with mild or moderate liver dysfunction. Pharmacokinetic data from patients with severe hepatic impairment (Child–Pugh Class C) are lacking.

Impaired absorption requiring an increased dose has been observed in a patient after Roux-en-Y gastric bypass surgery [284]. No pharmacokinetic data is available for patients younger than 18 years.

Until now, there is only one report on penetration of isavuconazole into human tissue. Isavuconazole levels in three soft tissue biopsies (muscle and fat) taken from a patient with mucormycosis 3 h after dosing were 1.09, 1.27 and 1.38 µg/g. The corresponding plasma level was 0.85 µg/mL [285]. Data from animal studies suggest a favourable tissue penetration. In a murine meningitis model, cerebral isavuconazole concentrations exceeded simultaneous plasma levels [286].

The standard dose of caspofungin is 70 mg as a single loading dose, followed by a maintenance dose of 50 mg once daily, or 70 mg once daily, when the body weight exceeds 80 kg. In healthy volunteers, a poly-exponential elimination with a t _½β of 8–10 h and a t _½γ of 27 h has been described (see Table 5). Caspofungin displays linear pharmacokinetics [313, 314]. A mean C _max of 12 µg/mL and a mean AUC_0–∞ of 118 µg h/mL were determined after a 70-mg single dose (T _inf = 1 h) [313]. Similar values were measured after a loading dose of 70 mg followed by a maintenance dose of 50 mg once daily for 14 days. No relevant accumulation took place, when this regimen was applied. AUC_0–24h was 97.6 and 100.5 µg h/mL on day 1 and on day 14, respectively. With daily doses of 50 and 70 mg, moderate accumulation of ~50% was observed within 2 weeks [314]. The caspofungin CL is about 10 mL/h/kg. Immediately after administration, caspofungin undergoes a rapid distribution into tissue, mainly into the liver. When ³H caspofungin had been infused 40% of the administered dose was found in the urine and 34% in the faeces [313, 314]. Caspofungin is bound to plasma proteins by 95% [313, 314]. A change in V _d with values of ~0.05 L/kg at the start of therapy and an increase to 0.3–2.0 L/kg within the first days of treatment has been reported [313]. In a phase II study of patients with proven or probable invasive aspergillosis, high-dose treatment with daily doses of 70, 100, 150, and 200 mg was assessed. Caspofungin displayed linear pharmacokinetics over the entire range. Body weight was found to be a significant covariate for CL. Patients with hepatic impairment, however, had been excluded from this study. After infusion of 200 mg of caspofungin, C _max and C _min amounted to 40.6 and 11.8 µg/mL, respectively, and the AUC was 500 µg h/mL [315, 316].

Caspofungin is transformed in the liver. Isoenzymes of CYP obviously have no relevant role in caspofungin metabolism. Caspofungin is hydrolysed to M0, its main metabolite which emerges in the plasma 24–30 h after infusion. Metabolite M1 is also formed by hydrolysis, and is N-acetylated forming M2. The metabolites M0, M1 and M2 are eliminated via the urine [317].

Caspofungin has no relevant influence on activity of CYP enzymes. In vitro, however, it was found to interfere with ATP-binding cassette transporters. Obviously it is a weak P-gp inhibitor, but a strong inhibitor of BCRP [200]. In clinical practice, drug–drug interactions are not a major problem in caspofungin treatment. When cyclosporine A was co-administered, caspofungin exposure was elevated by 35%. In contrast, tacrolimus caused slightly lowered C _max values of caspofungin. Caspofungin concentrations were also lowered by simultaneous administration of efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin or carbamazepine [318].

In allogenic haematopoietic stem cell transplant recipients, mean C _max (8.5 µg/mL) was similar to, and mean C _min (2.9 µg/mL) was slightly above the values reported from other study populations on standard dosage [319].

For patients with moderate hepatic impairment, reduction of the maintenance dose to 35 mg/d is advised. This recommendation is based on data obtained from patients with mild liver cirrhosis (Child–Pugh Score 5–6) or moderate liver cirrhosis (Child–Pugh Score 7–9) who were in an otherwise stable condition. The patients were matched to healthy subjects. Patients with moderate liver cirrhosis were treated with a reduced maintenance dose of 35 mg once daily, patients with mild cirrhosis with the standard dose. A slight elevation in caspofungin concentrations observed in mild hepatic insufficiency was judged as clinically irrelevant. In patients with moderately impaired liver function, the reduced dose led to caspofungin concentrations comparable with those in the control group [320]. In critical illness, patients with moderate liver dysfunction may achieve sub-therapeutic caspofungin exposure when the dose is adjusted (AUC_0–24 h was 65 instead of ~100 µg h/mL). This was recently found out by Martial and colleagues applying pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation. The authors ascribe the low concentrations to typical pathophysiological alterations occurring in critically ill patients, e.g. hypoalbuminaemia, and advise standard dose for this population [321]. In a critically ill male patient (body weight 85 kg with) suffering from liver cirrhosis (Child–Pugh Score 9), therapeutic caspofungin exposure has been achieved with administration of the standard dose [322].

In 38 critically ill patients treated with standard doses of caspofungin at a surgical ICU, C _min values were significantly higher when the body weight was <75 kg and the serum albumin level >23.6 g/L [323]. Recently, van der Elst et al. reported a median AUC_0–24 h of 78 µg h/mL from 20 patients treated at intensive care units (ICU) with standard doses. Thus, caspofungin exposure was somewhat lower than in healthy subjects and may result in sub-optimal efficacy. Based on their data and on population pharmacokinetic modelling the authors suggest a dose of 1 mg/kg bodyweight for critically ill patients [324]. Variable levels and an even lower exposure (mean AUC_0–24 h, 52 µg h/mL, mean C _max, 3.9 µg/mL) has been found by Sinnollareddy et al. in seven critically ill patients [157]. In contrast, pharmacokinetic parameters obtained from 21 ICU patients on caspofungin at standard doses were similar to those of non-critically ill patients. On day 7 of caspofungin treatment (n = 13), median AUC_0–24 h was 107.2 (90.4–125.3) µg h/mL, C _min 2.55 (1.82–3.08) µg/mL, C _max 8.65 (7.16–9.34) µg/mL, V _d 7.03 (5.51–7.73) L and CL 0.54 (0.44–0.60) L/h [median (interquartile range)] [325].

Since caspofungin elimination is largely independent from renal function, standard dosage is suggested in patients with renal impairment, even in those with terminal renal failure requiring haemodialysis (see Table 5) [318, 326]. Two studies have investigated the influence of continuous renal replacement therapy on caspofungin kinetics. In critically ill patients on continuous veno-venous haemofiltration or on continuous veno-venous haemodialysis, pharmacokinetic parameters were comparable with those in critically ill patients not on renal replacement therapy or in healthy volunteers. The extracorporeal caspofungin CL was negligible. Thus, standard dosage has therefore been advised for patients undergoing continuous renal replacement therapy [327]. More recently, Roger et al. performed a pharmacokinetic study in critically patients on vasopressor support undergoing veno-venous haemofiltration (n = 5) or veno-venous haemodiafiltration (n = 7). In addition, they performed population pharmacokinetic modelling and Monte Carlo simulations. Based on their results, they recommend an enhanced loading dose of 100 mg followed by standard maintenance dose [328].

Caspofungin plasma levels have also been reported from two critically ill patients on ECMO. In a young female on veno-arterial ECMO, most of the caspofungin levels were below the lower limit of detection [64]. In contrast, a male on veno-venous ECMO presented therapeutic C _min and C _max values [224].

In rats, caspofungin has reached relatively high tissue concentrations in the liver and the kidneys, intermediate concentrations in spleen, lung (mean 2.4 µg/g), red blood cells, and small intestine. In heart, lymph nodes, muscle, eyes and brain (mean 0.2 µg/g) caspofungin concentrations were low. The rats had been treated with a high a single dose of 2.0 mg/kg [H³] labelled caspofungin. In the liver, 22.2 µg/g (35% of the dose) on average was measured 24 h after injection. Lower concentrations were detected in lung and brain. [313]. In a patient with cholangitis, biliary caspofungin levels were measured after infusion of 70 mg using a bioassay. Levels amounted to 0.8 µg/mL at 1 h, to 1.0 µg/mL at 2 h, and to 0.6 µg/mL at 3 h after infusion. The serum concentration at 1 h was 3.1 µg/mL [329].

The recommend standard dose is 200 mg once on day 1 (loading dose) and 100 mg once daily on subsequent days (maintenance dose). The infusion rate should not exceed 1.1 mg/min. Therefore, a T _inf of 3 h is required for the loading dose and a T _inf of 90 min for the maintenance dose. For antifungal prophylaxis in immunocompromised patients, administration of 200 mg every 48 h and 300 mg every 72 h was compared with the standard regimen and resulted in similar AUC_0–144 h values [330].

Plasma pharmacokinetics of anidulafungin has been studied in healthy volunteers and in various patient populations [331]. A population pharmacokinetic analysis was performed on 600 plasma levels obtained from 225 subjects during phase II and phase III trials. A mean t _1/2 of 25.6 h, a V _ss of 32.5 L (0.54 L/kg) and a CL of 0.93 L/h (15 mL/h/kg) has been reported. A mean C _max of about 7 µg/mL has been measured after 100 mg per day; the AUC_0–∞ was 106 µg h/mL [246]. In nine healthy volunteers, who had obtained 90 mg of ¹⁴C-labeled anidulafungin, the mean C _max was 4.11 µg/mL, the AUC was 102.2 µg h/mL and the t _½ amounted to 28 h. Anidulafungin undergoes spontaneous ring opening. The respective product which is further degraded by hydrolysis and N-acetylation independently from phase I and II metabolism is eliminated via biliary excretion [303, 332]. The degradants of anidulafungin are eliminated mainly by the faeces. Only 10% of the administered radioactivity was recovered as intact drug, 90% as degradants (see Table 5).

Obviously, anidulafungin does not inhibit CYP isoenzymes. However, a strong in vitro inhibition of the ATP-binding cassette transporter BCRP by anidulafungin has been demonstrated [200]. Several clinical studies addressed eventual drug–drug interactions with anidulafungin, e.g. co-medication with voriconazole did not cause an interaction [333]. Simultaneous treatment with cyclosporine A (1.25 mg/kg orally applied) and anidulafungin resulted in a 22% increase in the AUC_0–∞ of anidulafungin. In vitro, anidulafungin exposure had no effect on the metabolism of cyclosporine A [334]. There was no relevant interaction between tacrolimus and anidulafungin in healthy volunteers [335].

Renal impairment has no influence on anidulafungin elimination [303]. Surprisingly, hepatic impairment results in a decreased anidulafungin exposure. An increased degradation due to a reduced protein binding and an enlarged V _d have been suggested as possible explanations [336]. In morbidly obese subjects, anidulafungin exposure was lowered by one-third on average. The authors conclude that an enhanced dose should be considered for this population. [337]. Based on pharmacokinetic/pharmacodynamic analyses of data from phase II and phase III studies, standard dosage has been recommend for patients with a body weight of up to 150 kg [338, 339]. In critically ill patients, Brüggemann et al. reported a median AUC_0–24 h of 83 µg h/mL, a C _max of 5.9 µg/mL, a C _min of 2.8 µg/mL, a t _½ of 27 h, and a median V _d of 40 L at day 7 of standard treatment. Thus, the exposure was slightly below that in healthy subjects or in patients in a more stable condition [340].

Renal replacement therapy by continuous veno-venous haemodiafiltration or continuous veno-venous haemofiltration did not affect anidulafungin pharmacokinetics, and there was no relevant extracorporeal CL [341‐343]. In a patients with liver failure treated with albumin dialysis, anidulafungin exposure was in the normal range although t _½ was only 18 h [344]. A patient treated with veno-venous ECMO for acute respiratory distress syndrome presented unchanged anidulafungin kinetics [345].

Anidulafungin tissue concentrations were assessed in rabbits after 7 days of treatment. After a bolus injection of 5 mg/kg, the highest concentrations were measured in lung (mean 17.9 µg/g) and liver (mean 16.8 µg/g) and the lowest concentrations were found in the brain (mean 1.6 µg/g), in the vitreous humour, the aqueous humour, and in the choroid. On day 7, the mean peak concentration in plasma reached 14.2 µg/mL [346]. Comparable concentrations were measured in rats with tissue half-lives of ~30 h. Tissue concentrations exceeded the simultaneous plasma levels ~tenfold [347]. High anidulafungin concentrations (mean 103.1 µg/mL) were measured in human pulmonary alveolar macrophages obtained from healthy volunteers after 3 days of standard treatment. Mean concentrations in pulmonary ELF and in plasma were lower (0.9 and 1.5 µg/mL, respectively) [229]. In blood, anidulafungin accumulates in peripheral blood mononuclear cells and in polymorphonuclear leukocytes [348].

Adults and children with a body weight >40 kg should receive 100 mg once daily for the treatment of invasive candidiasis, 150 mg for the treatment of oesophageal candidiasis (3 mg/kg/day for body weight ≤40 kg), and 50 mg once daily for Candida prophylaxis. In adult patients undergoing bone morrow or peripheral stem cell transplantation, on additional fluconazole prophylaxis, pharmacokinetics of micafungin was studied. On day 7 of treatment with a daily dose of 100 mg (T _inf = 1 h), the mean C _max was 22.0 µg/mL, the AUC_0–24 h amounted to 101.6 µg h/mL, t _½ was 12 h, CL was 1.1 L/h, and V _ss was 17.3 L. [349]. Micafungin has a very high protein binding of 99.85%. Micafungin is metabolised into largely inactive metabolites, i.e. a catechol form (M-1), a methoxy form of M-1 (M-2) and to a further metabolite M-5 formed by hydroxylation at the side chain. In vitro, micafungin is a substrate for CYP3A, but hydroxylation by CYP3A plays a minor role in vivo. The metabolites are excreted mainly via the faeces [304].

Micafungin appears to be effective against most Candida species when the AUC/MIC ratio exceeds 3000. Pharmacokinetic/pharmacodynamic targets for various body fluids remain to be established [350, 351]. In patients with Candida oesophagitis, administration of 300 mg every other day and 150 mg daily resulted in almost identical mean AUC_0–48 h values (311 versus 310 µg h/mL). There was a non-significant trend to better response in patients on intermittent high-dose treatment [295].

Micafungin is a weak inhibitor of CYP3A [352]. In vitro, it is a strong inhibitor of multidrug resistance protein 4 (MRP4) and a mild inhibitor of the transporters P-gp, multidrug resistance protein 1 (MRP1), multidrug resistance protein 5 (MRP5), and BCRP [200]. Accordingly, a 15%-reduction in CL of cyclosporine A was observed, when micafungin was concomitantly administered [353]. In contrast, micafungin had no influence on tacrolimus exposure in healthy volunteers [354]. The combination of fluconazole and micafungin had no effect on the pharmacokinetics of fluconazole or micafungin [355]. Induction of CYP3A4 by rifampicin or ritonavir did not exert an influence on the AUC_0–∞ of micafungin. Warfarin, diazepam, salicylic acid or methotrexate did not affect micafungin concentrations [356].

In patients with febrile neutropenia who had undergone recent allogenic haematopoietic stem cell transplantation, a micafungin dose escalation from 150 to 300 mg per day had no significant influence on cyclosporine A exposure as expressed by the ratios C _max/dose and C _min/dose [357]. Simultaneous administration of high-dose micafungin and low-dose amphotericin B deoxycholate in healthy males resulted in a 30% increase in amphotericin B concentrations but left micafungin levels unchanged [358].

Micafungin pharmacokinetics was investigated in children aged 2–12 years and in adolescents aged 13–17 years suffering from febrile neutropenia. Children were treated with 0.5–4.0 mg/kg/day, adolescents with 0.5–1.5 mg/kg/day. Administration of 2 mg/kg resulted in a C _max of 21.4 ± 9.7 µg/mL, an AUC_0–∞ of 132.3 ± 27.1 µg h/mL, on day 4 (mean ± standard error of the mean). CL was ~20 mL/h/kg, t _1/2, 12–13 h, and V _ss was 0.3–0.4 L/kg. Mean CL was faster in 2- to 8-year-old than in 9- to 17-year-old children [359]. A mean C _max of 2.5 µg/mL and an AUC of 20.6 µg h/mL were measured in premature infants after a single micafungin dose of 0.75 mg/kg; t _1/2 was 7.5 h [355]. In children with invasive candidiasis younger than 5 years old, the micafungin CL was faster and the exposure was lower than in those who were at the age of 5 years or over. A similar t _1/2 was found in both groups [360]. Recently, Hope and colleagues performed a population pharmacokinetic analysis on pharmacokinetic data of micafungin and its metabolites M1 and M5 obtained from 229 children between the ages of 4 month and 17 years enrolled in phase I and phase III trials. An AUC_0–24 h of 75–139 µg h/mL was set as a target. The authors propose a dose of 1 mg/kg for antifungal prophylaxis, 2 mg/kg for the treatment of invasive candidiasis, and a micafungin dose of 3 mg/kg for the treatment of Candida oesophagitis [361].

A study on liver homogenates from neonates and adults suggests that the faster micafungin CL observed in neonates is a result of a higher unbound micafungin fraction in neonatal serum in comparison with adults (mean 0.033 versus 0.004). The expression levels of various transporter proteins, i.e. sodium/taurocholate co-transporting polypeptide (NTCP), organic anion-transporting polypeptides 1B1/3 (OATP1B1/3), BSEP, BCRP and multidrug resistance-associated protein 3 (MRP3 or ABCC3), were similar in neonates and in adults [362].

As mentioned above, the use of micafungin in patients with hepatic impairment is discouraged by the European product information, because of its hepatotoxicity. Like for anidulafungin, the micafungin exposure was significantly reduced in patients with moderately impaired liver function (Child–Pugh score 7–9) in comparison with healthy volunteers (mean AUC_0–∞, 97.5 versus 125.9 µg h/mL, P = 0.03). However, this difference was ascribed to different body weights in both groups. Therefore, no dose adjustment is recommended in moderate hepatic impairment [355, 363]. A lower micafungin exposure and an increased CL were also found in a single-dose study of 8 patients with severe hepatic dysfunction and of 8 healthy subjects. Mean values were 7.3 versus 10.3 μg/mL for C _max, 100 versus 142 μg h/mL for AUC_0–24 h, and 0.7 versus 1.1 L/h for the micafungin CL in subjects with severely impaired and normal liver function, respectively [364]. No correlation between the degree of liver dysfunction and micafungin levels could be identified in a study of 8 patients with pre-existing hepatic impairment. Due to liver toxicity, however, micafungin treatment had to be stopped in one of the patients [365]. By contrast, C _min and C _max of micafungin were significantly enhanced in patients with liver failure caused by graft versus host disease after haematopoietic stem cell transplantation. When serum bilirubin concentration was >5 mg/dL and/or serum γ-glutamyltransferase level was >500 IU/L, median C _min was 10.5 and C _max was 27.6 µg/mL. In patients with lower bilirubin and γ-glutamyltransferase, the values amounted to 4.8 and 15.8 µg/mL, respectively [366]. Thus, the effect of impaired liver function on micafungin pharmacokinetics appears to be variably and hardly predictable.

Micafungin pharmacokinetics is unchanged in renal impairment [363, 366]. Three clinical studies addressed the effect of continuous renal replacement therapy on micafungin elimination. Neither continuous veno-venous haemodialysis nor continuous veno-venous haemodiafiltration nor continuous veno-venous haemofiltration had a clinically relevant influence on micafungin CL. Thus, no dose adjustment is required for patients undergoing continuous renal replacement therapy [367‐369]. By contrast, an 8-h plasma exchange has shortened t _1/2 of micafungin from 16.5 to 6.3 h and increased CL from 0.37 to 0.93 L/h. Administration after plasma exchange and an increment in dose have therefore been suggested [370].

In 20 critically ill patients treated with 100 mg of micafungin per day, micafungin exposure was somewhat lower than that in healthy volunteers and patients in a more stable condition. The median AUC_0–24 h was 78.6 µg h/mL, median C _max was 7.2 µg/L, C _min was 1.55 µg/L, V _d was 25.6 L, CL was 1.3 L/h, and t _1/2 amounted to 13.7 h on average [371]. Thus, exposure was lower than that reported from stem cell transplant recipients [349]. Jullien et al. have performed a population pharmacokinetic analysis of 100 critically ill patients on mechanical ventilation suffering from severe sepsis. The mean micafungin CL amounted to 1.34 L/h. Monte Carlo simulation was applied for the assessment of the probability of target attainment. By the standard dose of 100 mg once daily, a sufficient exposure was achieved in ≥90% of the patients for infections with C. albicans or C. glabrata with an MIC <0.015. A higher dose is suggested, for infections with C. parapsilosis or with less susceptible C. albicans or C. glabrata strains [372].

In a study of 12 infants on ECMO, Autmizguine et al. observed a slightly increased V _d and a micafungin CL in the upper normal range. The authors propose a prophylactic dose of 2.5 mg/kg and a therapeutic dose of 5 mg/kg once daily for this population [373]. Micafungin exposure was high (C_max, 17.4, C_min, 5.5 µg/mL, AUC_0–24 h, 207.3 µg h/mL, t_1/2, 20 h, CL, 0.3 L/h, dose, 100 mg once daily) in a malnourished critically ill patient on extracorporeal carbon dioxide removal and continuous haemofiltration. An increased micafungin elimination by extracorporeal carbon dioxide removal is therefore unlikely [374].

In HIV-infected patients with confirmed oesophageal candidiasis, micafungin pharmacokinetics was similar to that in healthy volunteers [375].

Micafungin tissue concentrations were measured in rats and rabbits after administration of 1 mg/kg. In rats, the highest micafungin concentrations were found in lung (mean 5.95 µg/mL) and kidney (mean 3.78 µg/mL) followed by liver (mean 2.65 µg/mL) [376]. In rabbits, tissue levels were comparable, and concentrations in brain (mean 0.10 µg/g), choroid (mean 0.061 µg/mL), and vitreous humour (mean 0.015 µg/mL) were very low [377].

Micafungin concentrations achieved in alveolar macrophages, ELF, and plasma of healthy volunteers amounted to a mean of 14.6, 0.52 and 14.8 µg/mL, respectively, after administration of 150 mg daily for 3 days [378]. A similar micafungin distribution has been found in adult lung transplant recipients after the same treatment. Mean C _max in plasma, ELF, and alveolar cells were 4.93, 1.38, and 17.41 µg/mL, respectively. For susceptible A. fumigatus with an MIC of 0.0156 µg/mL, AUC_0–24 h/MIC ratios of 5077, 923, and 13340 were calculated for plasma, ELF, and alveolar cells, respectively [379].

In pancreatic pseudocyst fluid, a micafungin concentration of 0.38 µg/mL was measured 24 h after administration [380]. Yamada et al. assessed the distribution of micafungin in CSF, pleural effusion, ascites, and wound secretion of seven patients with IFIs. After daily doses of 100–300 mg of micafungin, highest concentrations were measured in wound secretion (4.4 µg/mL), and surprisingly, in CSF (1.9 µg/mL). Micafungin concentrations in pleural effusion (0.7 µg/mL) and in ascites (1.0 µg/mL) were lower [381]. In peritoneal fluid of critically ill post-surgical patients with peritonitis, a median C _max of 1.2 µg/mL was measured [351]. In bile of a patient suffering from Candida cholangitis, the micafungin concentration was 1.9 µg/mL 24 h after infusion of 150 mg [382].

In a burn patient on 200 mg of micafungin once daily, C _min levels in eschar were 4.0 and 14.8 µg/mL after a single dose and after repeated doses, respectively [383, 384]. Later on, micafungin concentrations in burn eschar and in plasma have been assessed in three other patients. By administration of 200 mg once daily, C _min levels in eschar of 1.4 and 6.7 µg/mL were achieved after the first dose and at steady state, respectively [383, 384]. Population pharmacokinetics of micafungin was analysed in burn eschar and plasma of 15 patients with severe burn injuries. Daily doses of 100–150 mg had been applied. The mean concentration in burn eschar amounted to 0.7 µg/mL and was below the detection limit in 1 patient. The probability of target attainment was estimated based on target AUC_0–24 h/MIC ratios of 285 and 3000 for C. parapsilosis and C. non-parapsilosis, respectively. By a single dose of 100 mg, targets were achieved for strains with low MICs of ≤0.008 and ≤0.064, respectively [385].

Intraocular penetration of 150–300 mg of intravenous micafungin per day was studied after vitrectomy in 7 patients. The mean micafungin concentrations were 21.02 µg/mL in the plasma, 0.10 µg/mL in the vitreous humour, and 0.08 µg/mL in the aqueous humour. Lower levels of 0.043 and 0.026 µg/mL had previously been measured in a single patient. Thus, micafungin penetration into aqueous and vitreous humour appears to be poor. Micafungin levels of 1.60–5.99 µg/g in the cornea, 14.65 µg/g in the iris, 1.20 µg/g in the retina, and 5.81 µg/g in the choroid were measured in material from single cases [386, 387].

Candidaemia is the most common manifestation of systemic candidiasis. Recent epidemiological studies revealed a rate of ~1.5 per 1000 hospital admissions and an overall 30-day mortality of 35%. C. albicans has been isolated in ~50% of the cases [14, 388]. Echinocandins are first-line drugs for the treatment of candidaemia [12, 13, 308]. Their elimination is independent from renal function. Impaired liver function can lead to increased caspofungin levels, but decreased exposure to anidulafungin and variable alterations of micafungin concentrations. Fluconazole can be used in stable patients with candidaemia at low risk of a resistant pathogen and for step-down therapy. It displays favourable tissue distribution and safety. Renal impairment requires dose reduction. As a strong inhibitor of CYP3A4 and CYP2C9, it causes various drug–drug interactions. Liposomal amphotericin B is an alternative to echinocandins and is indicated for treatment of central nervous and cardiovascular candidiasis. Although safer than the conventional amphotericin B deoxycholate, a considerable nephrotoxicity of liposomal amphotericin B has to be anticipated. Whereas high-dose echinocandins might be an alternative for treatment of Candida endocarditis, their use in CNS infections is discouraged because of insufficient target-site penetration. Amphotericin B deoxycholate is recommended for disseminated candidiasis in neonates [12]. In adults, it should be avoided because of its nephrotoxicity and infusion-related adverse effects. Continuous infusion will reduce amphotericin B toxicity but eventually also its efficacy. Only fluconazole, conventional amphotericin B deoxycholate, and flucytosine reach therapeutic urinary concentrations. Echinocandins and amphotericin B lipid formulations are therefore not useful for treatment of urinary Candida infections. When 5-flucytosine is applied, its dose has to be adjusted to renal function and close monitoring of drug levels, as well as hepatotoxic and myelotoxic effects is strongly recommended.

Voriconazole is the drug of choice for the treatment of invasive aspergillosis [10]. It penetrates well into relevant target compartments. However, its complex, non-linear pharmacokinetics requires therapeutic drug monitoring. Voriconazole is involved in numerous drug–drug interactions, e.g. with immunosuppressives, sedatives, anticoagulants, and lipid lowering drugs. CNS and liver are the major targets of voriconazole toxicity. Liposomal amphotericin B is a therapeutic alternative, particularly when azole resistance is a concern. Posaconazole and isavuconazole are options for second-line treatment, but their role is not yet established. Data on their tissue penetration are incomplete.

Cryptococcosis is an indication for combined antifungal therapy with amphotericin B and 5-flucytosine [389]. As renal deterioration is common under amphotericin B treatment, even with the liposomal formulation, close monitoring of renal function and of flucytosine levels, if available, is mandatory. Flucytosine easily penetrates into relevant tissues including the CNS. Myelo- and hepatotoxicity limit its used.

The drug of choice for mucormycosis is liposomal amphotericin B at a dose of 5 mg/kg. For CNS manifestation, even 10 mg/kg are required. The current European guidelines recommend posaconazole as an option for the second-line or savage therapy, although this is off-label [11]. If posaconazole is selected, the recently introduced intravenous formulation should be used in order to warrant therapeutic exposure.

In critically ill patients, characteristic pathophysiological changes such as altered hydration, haemodynamics, tissue perfusion, and plasma protein levels can reduce exposure to antifungals. In general, this effect is more pronounced for hydrophilic drugs. Lower levels of liposomal amphotericin B and in some studies of echinocandins have been reported for critically ill patients. Sufficient dosage, in particular adequate loading doses, is therefore pivotal. The initial dosage must be guided by V _d. Eventually impaired elimination has to be considered during further treatment. Therapeutic drug monitoring should be used in this population.

Flucytosine and fluconazole are mainly eliminated via the kidneys. Dose reduction guided by glomerular filtrations rate is therefore required in patients with renal impairment for these drugs (see Tables 2 and 3). Amphotericin B deoxycholate is contra-indicated in patients with potentially reversible renal impairment. No dose adjustment is recommended for liposomal amphotericin B in patients with impaired renal function. However, also this formulation displays a considerable nephrotoxicity. Echinocandins and the broad spectrum azoles voriconazole, posaconazole, and isavuconazole can be given at standard dose in renal failure. Accumulation of the solvent SBECD must be considered for the intravenous forms of voriconazole and posaconazole. Hepatic impairment affects pharmacokinetics of echinocandins. A dose reduction has been recommended for caspofungin when liver dysfunction is moderate. However, underdosage is a concern, particularly in critically ill patients. Anidulafungin can be applied at standard dose, although its levels may be slightly reduced in patients with impaired liver function. Micafungin should be avoided in liver disease. The maintenance dose of voriconazole should be reduced by 50% when it is applied in patients with liver cirrhosis Child–Pugh A and B. We recommend therapeutic drug monitoring in this case. For posaconazole and isavuconazole, no dose adjustment is recommended in patients with liver dysfunction. Drug monitoring and clinical monitoring for toxic effects, however, should be performed.

For intermittent haemodialysis, the dose of 5-flucytosine should be reduced to 37.5 mg/kg once after haemodialysis. Fluconazole should be applied at a maintenance dose of 100–200 mg after haemodialysis. For 5-flucytosine treatment during continuous renal replacement therapy, doses between 2.5 g every 72 h and 2.5 g twice daily have been proposed. As there are recent reports on overdosage and severe toxicity, we strongly advise therapeutic drug monitoring to avoid harmful adverse effects in this situation. Fluconazole has to be applied at enhanced maintenance doses of 800 and 1200 mg per day during continuous haemofiltration and haemodiafiltration, respectively. Enhanced doses during continuous renal replacement therapy are also required for itraconazole. Standard doses are appropriate during continuous renal replacement therapy for lipid-formulated amphotericin B, for echinocandins, for voriconazole, and for posaconazole. In patients on intermittent haemodialysis, the SBECD containing intravenous formulations should be avoided, if possible. Antifungal pharmacokinetics during ECMO has been assessed in a few cases rendering conflicting data for caspofungin and voriconazole.

So far there have not been too many indications to apply CAF therapy in Candida infections. A combination therapy based on lipid formulations of amphotericin B and flucytosine is recommended in the treatment of intracranial infections, including endophthalmitis [391]. A study on an animal model with Candida meningoencephalitis revealed that liposomal amphotericin B achieved higher concentration in the brain than amphotericin B lipid complex or amphotericin B deoxycholate [417].

A similar CAF formula is used for native valve endocarditis infected by a ventricular assist device (VAD), implantable cardioverter-defibrillator (ICD) or pacemaker [391, 418]. In spite of strong recommendation to use this combination of drugs, there is low quality of evidence concerning this issue. Since the introduction of echinocandins routine application of CAF therapy for candidaemia has not been advised [12]. There have been reports on fluconazole combined with flucytosine applied to a few patients in the treatment of Candida meningitis but it is generally thought that this CAF therapy is possible as a step-down therapy [419].

CAF therapy applied in mould infections arouses big interest due to the high mortality it causes and due to its costs. There are contradictory conclusions of studies on the application of CAF in invasive aspergillosis. So far, research could not definitely confirm superiority of CAF. The results chiefly depend on the population of patients and their clinical state, the type of pathogen and its resistance, the location of infection (pulmonary versus extra-pulmonary), CAF heterogeneity, the presence of neutropenia, immunosuppressive regimens, the duration of therapy, various endpoints and follow-ups, etc. [420]. It is estimated that about 30–50% of ICU patients receive CAF therapy in invasive Aspergillus infections [421]. Although the caspofungin and liposomal amphotericin B combination was more successful as a primary rather than salvage therapy and it resulted in a favourable response in 60% patients [422] and despite the fact that the administration of voriconazole plus caspofungin as a primary therapy in organ transplant recipients improved the 90-day survival rate [423], there is no sufficient data to recommend routine application of CAF therapy as primary therapy in invasive Aspergillus infections [424].

A meta-analysis of 16 studies on 1833 patients shows that a double antifungal therapy increases the likelihood of therapeutic success and improves the 12-week survival rate, as compared with monotherapy in a salvage setting. Up to 30% of ICU patients receive this therapy for invasive aspergillosis (in breakthrough or refractory invasive aspergillosis) [397, 420, 421, 425].

The application of voriconazole and caspofungin combination as a salvage therapy (in the case of failure of amphotericin B therapy) caused synergistic interaction against Aspergillus (simultaneous inhibition of the cell membrane and fungal cell wall biosynthesis) and improved 3-month survival, as compared with voriconazole alone. The probability of death was the lowest in patients who received CAF therapy [426].

Although clinical trials did not reveal antagonism between azoles and amphotericin B, the application of this combination is not sufficiently justified and currently it is not recommended to administer polyenes and azoles to patients simultaneously [37].

CAF therapy based on voriconazole administered with anidulafungin [427] or micafungin [428, 429] had poor antifungal efficacy or missed statistical significance.

In a recently published study conducted on a homogenous group of haematological patients who received voriconazole and anidulafungin versus voriconazole alone, there was no significant difference in mortality between CAF and monotherapy. Nevertheless, the research proved that patients with a positive galactomannan test result and radiographic findings were characterised by reduced overall mortality in CAF therapy (15.7%) versus monotherapy (29.3%) (P = 0.037) [430].

Thus, in specific clinical situations (bilateral inflammatory infiltrations of the lungs, respiratory failure, sepsis/septic shock, unsuccessful monotherapy), the use of a triazole (voriconazole) or lipid amphotericin B formulation in combination with an echinocandin should be considered as salvage therapy [420, 421]. The type of antifungal applied in combination therapy depends on the Aspergillus species, organ function (chiefly kidney and liver function) and the need of other drugs which may cause drug–drug interactions, especially with voriconazole (voriconazole is metabolised by, and inhibits enzymes in the cytochrome system P450: CYP2C19, CYP2C9 and CYP3A4) [421, 431]. To sum up, CAF therapy for invasive aspergillosis is most recommended in patients with haematological malignancies and an elevated galactomannan levels. Apart from that, it seems that in CAF therapy for invasive Aspergillus infections voriconazole plus echinocandin or amphotericin B combined with an echinocandin are preferable combinations. CAF can be used as a salvage therapy in high risk patients [432]. However, in the recently published guidelines CAF therapy with voriconazole and an echinocandin is discouraged, but may be considered as a primary management in select patients with documented invasive aspergillosis (weak recommendation) [10].

The combination of amphotericin B and flucytosine became a standard in treating cryptococcal meningitis [433] when Bennett et al. confirmed that the combination was more efficacious than amphotericin B administered as a monotherapy [434]. CAF therapy resulted in lesser toxicity and significantly faster sterilisation of CSF. There were similar results of other studies on cryptococcal meningitis in patients infected with human immunodeficiency virus (HIV) [435]. The combination of amphotericin B and flucytosine resulted in reduced risk of mortality on the 14th and 70th day in comparison with patients receiving amphotericin B as a monotherapy and it exhibited improved early fungicidal activity (EFA) [435]. Flucytosine quickly diffuses into the CSF; hence its efficacy in treating intracranial fungal infections [436]. O’Connor and colleagues found that the combination of liposomal amphotericin B and flucytosine applied to treat cryptococcal meningoencephalitis exhibited additive effect in the central nervous system and resulted in a dose-dependent reduction of the fungal burden. The administration of liposomal amphotericin B dosed at 3 mg/kg/day plus flucytosine 50 mg/kg/day, and liposomal amphotericin B 3 mg/kg/day plus flucytosine 100 mg/kg/day achieved near-maximum antifungal activity and it was significantly less toxic [437]. The role of azoles (fluconazole) in treatment of cryptococcal infections is usually limited to a maintenance therapy in the form of monotherapy after combined induction therapy [438]. However, due to the unavailability of flucytosine in some countries a combination of a short administration of amphotericin B and larger doses of fluconazole (1200 mg/day) is used. The combination resulted in improved EFA in the CSF and lower toxicity of the therapy [432, 439]. If it was impossible to apply a lipid formulation of amphotericin B, CAF therapy based on fluconazole and flucytosine was applied. It improved the survival rate and reduced the time of CSF sterilisation [440]. Thus, in cryptococcal diseases (meningitis, encephalitis) CAF therapy with amphotericin B plus flucytosine remains a treatment of choice, especially in HIV-infected patients. If flucytosine is unavailable, fluconazole is recommended as an alternative [389, 432].

Zygomycosis is a rare infection due to mould fungi of the Zygomycota, preferentially called mucormycosis. Zygomycota cause a life-threatening infection involving most commonly lung and rhino-orbital-cerebral locations, mostly in immunocompromised patients (neutropenia, immunosuppressive drugs, penetrating trauma, diabetes) [441]. Despite therapy (elimination and/or reversal of underlying risk factors, surgical debridement, antifungals), the overall mortality is >50% and approaches 100% in disseminated forms [441]. The standard medical therapy includes liposomal amphotericin B, which is the most effective agent, whereas in the case of refractory disease or intolerance to prior antifungal therapy, CAF therapy is postulated, though with a moderate strength recommendation [11]. The use of polyene–caspofungin CAF therapy is interesting from the point of view of the mechanism of action of caspofungin, which in filamentous fungi is rather fungistatic. In vitro caspofungin is inactive against Mucorales, but in combination with liposomal amphotericin B enhances its action in some species, especially in relation to Rhizopus spp., the most common identified pathogens. Namely, 1,3-β-d-glucan synthase in yeast cells contains a regulatory subunit encoded by RHO1 and a catalytic subunit encoded by FKS, which is simultaneously the target for echinocandins. Thus, membrane-associated 1,3-β-d-glucan synthase activity is inhibited by caspofungin, which in combination with liposomal amphotericin B significantly improves the outcomes and long-term survival compared to monotherapy [441, 442]. Within the other antifungals, posaconazole seems to have the most effective activity against Mucorales. The analyses suggest that a CAF treatment with liposomal amphotericin B and posaconazole may be considered when dealing with patients presenting highly aggressive forms of an invasive mucormycosis [443]. In case of amphotericin B intolerance, CAF therapy with caspofungin plus posaconazole has been applied with positive effect. Sheybani et al. present two cases treated successfully with this combination and suggest that caspofungin might affect the efficacy of posaconazole in an additive or even synergistic manner, although Mucorales are resistant to caspofungin [444].